High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting

Mol Metab. 2017 Jan 12;6(3):236-244. doi: 10.1016/j.molmet.2017.01.003. eCollection 2017 Mar.

Abstract

Objective: α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER "knock-in" mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreERT2 mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing.

Methods: We utilized CRISPR-Cas9 technology to insert an IRES-CreERT2 sequence into the 3' UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreERT2 mice. Recombination efficiency in GCG+ pancreatic α-cells and glucagon-like peptide 1 positive (GLP1+) enteroendocrine L-cells was measured in Gcg-CreERT2 ;Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood.

Results: Tamoxifen injection of Gcg-CreERT2 ;Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreERT2 allele were phenotypically normal.

Conclusions: We successfully derived a Gcg-CreERT2 mouse line that expresses CreERT2 in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types.

Keywords: CRISPR; CRISPR, clustered regularly interspaced short palindromic repeat; Cre, Cre recombinase; CreERT2, tamoxifen-inducible Cre recombinase-estrogen receptor fusion protein; DAPI, 4′,6-diamidino-2-phenylindole; ESC, embryonic stem cell; Enteroendocrine L-cell; FACS, fluorescence-activated cell sorting; GCG, glucagon; GLP1; GLP1, glucagon-like peptide 1; Glucagon; IRES, internal ribosomal entry site; Islet; LSL, loxP-stop-loxP; UTR, untranslated region; YFP, yellow fluorescent protein; gRNA, guide RNA; α-cell.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions / genetics
  • Animals
  • CRISPR-Cas Systems / drug effects
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / metabolism
  • Gene Knock-In Techniques
  • Gene Targeting
  • Genetic Engineering / methods*
  • Genetic Techniques
  • Glucagon / genetics*
  • Glucagon / metabolism
  • Glucagon-Secreting Cells / metabolism
  • Glucagon-Secreting Cells / physiology
  • Islets of Langerhans / drug effects
  • Mice
  • Mice, Transgenic / genetics*
  • Tamoxifen / pharmacology
  • Transgenes / drug effects

Substances

  • 3' Untranslated Regions
  • Tamoxifen
  • Glucagon